Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Peter D. Cole, Christine Mauz-Körholz, Maurizio Mascarin, Gérard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Loredana Amoroso, Salvatore Buffardi, Charlotte Rigaud, Markus Puhlmann, Stephen Francis, Mariana Sacchi, Richard A. Drachtman, Paul David Harker-Murray, Thierry Leblanc, Stephen Daw, Kara M. Kelly
Institutions: Rutgers Cancer Institute, Justus-Liebig-Universität Gießen, Martin Luther University Halle-Wittenberg, Centro di Riferimento Oncologico, Hôpital de la Timone, Johns Hopkins Hospital, Princess Máxima Center, Seattle Children's Hospital, Istituto Giannina Gaslini, Institut Gustave Roussy, Seagen (United States), Bristol-Myers Squibb (United States), Children's Hospital of Wisconsin, Hôpital Robert-Debré, University College Hospital, University College London, Roswell Park Comprehensive Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3032451362